TamirBio

TamirBio’s initial clinical target is the treatment of HPV. Worldwide, there are 14 million new and recurrent infections caused by HPV (the most common sexually transmitted disease). Today’s therapeutic options all have shortcomings including high rates of recurrence, the need for continued application, or invasiveness. TamirBio asserts that clinicians and patients will adopt a topically applied option that demands only 1-2 applications with a high safety profile.